CAS 151038-96-9: DOXO-EMCH

Descrição: DOXO-EMCH, com o número CAS 151038-96-9, é um composto químico que serve como um profármaco da doxorubicina, um conhecido agente quimioterápico. Este composto é caracterizado por sua capacidade de liberar seletivamente doxorubicina em tecidos-alvo, aumentando a eficácia terapêutica do medicamento enquanto minimiza a toxicidade sistêmica. DOXO-EMCH é tipicamente projetado para melhorar a farmacocinética e a biodistribuição da doxorubicina, permitindo um tratamento mais eficaz do câncer. A estrutura de DOXO-EMCH inclui um conector que facilita a liberação de doxorubicina após a clivagem enzimática, que muitas vezes é mediada por enzimas específicas presentes no microambiente tumoral. Essa abordagem direcionada visa aumentar a concentração do fármaco ativo no local do tumor, melhorando assim o resultado geral do tratamento. Além disso, a solubilidade, estabilidade e perfil metabólico do composto são cruciais para seu desempenho em ambientes clínicos. À medida que a pesquisa avança, DOXO-EMCH representa uma avenida promissora no desenvolvimento de terapias contra o câncer mais eficazes com efeitos colaterais reduzidos.

Fórmula: C₃₇H₄₂N₄O₁₃

InChI: InChI=1S/C37H42N4O13/c1-17-32(46)20(38)13-27(53-17)54-22-15-37(51,23(16-42)39-40-24(43)9-4-3-5-12-41-25(44)10-11-26(41)45)14-19-29(22)36(50)31-30(34(19)48)33(47)18-7-6-8-21(52-2)28(18)35(31)49/h6-8,10-11,17,20,22,27,32,42,46,48,50-51H,3-5,9,12-16,38H2,1-2H3,(H,40,43)/t17-,20-,22-,27-,32+,37-/m0/s1

Chave InChI: InChIKey=OBMJQRLIQQTJLR-FRTGXRTISA-N

SMILES: O=C1C=2C=CC=C(OC)C2C(=O)C=3C(O)=C4C(=C(O)C13)CC(O)(C(=NNC(=O)CCCCCN5C(=O)C=CC5=O)CO)CC4OC6OC(C)C(O)C(N)C6

Sinónimos:

• 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, (1-(4-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-hydroxyethylidene)hydrazide, (2S-cis)-
• 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, 2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide
• 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, [1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide
• 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, [1-[4-[(3-amino-2,3,6-trideoxy-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide, (2S-cis)-
• 2,5-Dihydro-2,5-dioxo-1H-pyrrole-1-hexanoic acid (1-(4-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-hydroxyethylidene)hydrazide, (2S-cis)-
• Aldoxorubicin
• Doxo-Emch
• Doxorubicin-EMCH
• MC-Doxhzn
• N'-[(1E)-1-{4-[(3-amino-2,3,6-trideoxyhexopyranosyl)oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl}-2-hydroxyethylidene]-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide
• 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, 2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide
• 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, [1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide
• 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, [1-[4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide, (2S-cis)-
• Doxorubicin(6-maleimidocaproyl)hydrazone

1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, 2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide

CAS: 151038-96-9

• Fórmula: C₃₇H₄₂N₄O₁₃
• Peso molecular: 750.7484

Doxorubicin-hydrazone-caproyl-maleimide

CAS: 151038-96-9

• Fórmula: C₃₇H₄₂N₄O₁₃
• Cor e Forma: Neat
• Peso molecular: 750.75

Doxorubicin-hydrazone-caproyl-maleimide

CAS: 151038-96-9

a 6-maleimidocaproyl hydrazone derivative of Doxorubicin which is an albumin binding prodrug. It is acid …

• Fórmula: C₃₇H₄₂N₄O₁₃
• Pureza: Min. 95%
• Cor e Forma: Powder
• Peso molecular: 750.75 g/mol

MC-DOXHZN

CAS: 151038-96-9

Mc-doxhzn is a protein-binding prodrug of DOXUbicin (DNA topoisomerase II inhibitor) with acid sensitivity.

• Fórmula: C₃₇H₄₂N₄O₁₃
• Pureza: 98%
• Cor e Forma: Solid
• Peso molecular: 750.75